Can Drosophila melanogaster represent a model system for the detection of reproductive adverse drug reactions?
Once a molecule is identified as a potential drug, the detection of adverse drug reactions is one of the key components of its development and the FDA approval process. We propose using Drosophila melanogaster to screen for reproductive adverse drug reactions in the early stages of drug development. Compared with other non-mammalian models, D. melanogaster has many similarities to the mammalian reproductive system, including putative sex hormones and conserved proteins involved in genitourinary development. Furthermore, the D. melanogaster model would present significant advantages in time efficiency and cost-effectiveness compared with mammalian models. We present data on methotrexate (MTX) reproductive adverse events in multiple animal models, including fruit flies, as proof-of-concept for the use of the D. melanogaster model.
Avanesian
Agnesa
A
Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA.
Semnani
Sahar
S
Jafari
Mahtab
M
D000818:Animals; D003362:Cost-Benefit Analysis; D004331:Drosophila melanogaster / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D015195:Drug Design; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000633:toxicity*; D023421:Models, Animal; D012098:Reproduction / Q000187:drug effects*; D013045:Species Specificity
D008727:Methotrexate